Janux Therapeutics (JANX)
(Real Time Quote from BATS)
$35.68 USD
+0.39 (1.11%)
Updated Aug 8, 2024 09:34 AM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
JANX 35.68 +0.39(1.11%)
Will JANX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for JANX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for JANX
Janux Therapeutics, Inc. (JANX) Reports Q2 Loss, Tops Revenue Estimates
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Misses Revenue Estimates
JANX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's What Could Help Janux Therapeutics (JANX) Maintain Its Recent Price Strength
Janux (JANX) Rises Almost 50% in a Week on Buyout Rumors
Janux Therapeutics (JANX) is on the Move, Here's Why the Trend Could be Sustainable
Other News for JANX
Janux Therapeutics GAAP EPS of -$0.11 beats by $0.21, revenue of $8.89M beats by $8.03M
Janux Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
JANX Stock Earnings: Janux Therapeutics Beats EPS, Beats Revenue for Q2 2024
TD Cowen Keeps Their Buy Rating on Janux Therapeutics Inc (JANX)
Janux Therapeutics reports Q2 EPS (11c), consensus (31c)